DC Deep Dive: Jonathan Miller Testifies on Lack of FDA Regulation for CBD Products
On Thursday, July 27th at 2:00 PM ET, U.S. Hemp Roundtable General Counsel, Jonathan Miller, testified during a historic hearing on hemp and CBD before the House Oversight and Accountability Committee’s Subcommittee on Health Care and Financial Services. The hearing, “Hemp in the Modern World: The Years long Wait for FDA Action,” was the first time Congress has formally scrutinized the impact of the U.S. Food and Drug Administration’s (FDA) failure to develop a regulatory pathway for the sale of ingestible hemp products such as CBD.
During the historic hemp hearing on Capitol Hill, Frost Brown Todd Attorney and CivicPoint Principal Jonathan Miller's testimony stood out as a crucial aspect of the proceedings. As a prominent figure in the hemp industry, Miller provided valuable insights into the urgent need for clear and science-based regulations. His testimony emphasized the importance of ensuring product safety, standardization, and consumer confidence within the industry.
Drawing upon his extensive expertise in the legal and policy aspects of the hemp sector, Miller advocated for sensible regulations that strike a balance between consumer safety and industry growth. He highlighted the necessity of distinguishing hemp-derived CBD from marijuana and establishing dosage guidelines and accurate labeling requirements to provide consumers with reliable information.
Jonathan Miller's testimony underscored the impact of the FDA's regulatory inaction on the hemp industry's growth potential and raised awareness about the risks posed by unregulated and inferior products in the market. By presenting evidence-backed arguments and advocating for collaborative efforts among industry stakeholders and lawmakers, Miller's testimony played a vital role in advancing the case for comprehensive and science-driven regulations during the hearing.